Association of Maternal Hypertensive Disorders During Pregnancy With Severe Bronchopulmonary Dysplasia: A Systematic Review and Meta-Analysis

Gina Lim, Yoo Jinie Kim, Sochung Chung, Yong Mean Park, Kyo Sun Kim, and Hye Won Park

Abstract

Background: This meta-analysis was performed to examine the association between maternal hypertension during pregnancy (HDP) and neonatal bronchopulmonary dysplasia (BPD).

Methods: We systematically searched PubMed, EMBASE, the Cochrane Library, and the KoreaMed database for relevant studies. We used the Newcastle-Ottawa Scale for quality assessment of all included studies. The meta-analysis was performed using Comprehensive Meta-Analysis software (version 3.3).

Results: We included 35 studies that fulfilled the inclusion criteria; the total number of infants evaluated came to 97,399 through review process. Maternal HDP was not significantly associated with any definition of BPD, i.e., oxygen dependency at 36 weeks of gestation (odds ratio [OR], 1.162; 95% confidence interval [CI], 0.991 – 1.362; P = 0.064) in pooled analysis of 29 studies or oxygen dependency at 28 days of age (OR, 1.084; 95% CI, 0.660– 1.780; P = 0.751) in pooled analysis of 8 studies. Maternal HDP was significantly associated only with severe BPD (OR, 2.341; 95% CI, 1.726–3.174; P < 0.001). BPD was not associated with HDP in the overall analysis (OR, 1.131; 95% CI, 0.977–1.309; P = 0.100) or subgroup analysis according to the definition of HDP.

Conclusion: Maternal HDP was not associated with neonatal BPD defined by the duration of oxygen dependency (at either 36 weeks of gestation or 28 days of life) but was associated with severe BPD.

Keywords: Bronchopulmonary Dysplasia; Hypertension, Pregnancy Induced; Infant, Newborn

Introduction

Bronchopulmonary dysplasia (BPD) is characterized by prolonged oxygen dependency or ventilator support of preterm infants. Various perinatal factors may affect BPD development, including lung damage and impaired alveolar and vascular development. Efforts have been made to predict the occurrence of BPD soon after birth and to prevent BPD in preterm infants using various ventilator strategies and the early caffeine use. However, the incidence of BPD has not decreased over the past 10 years in infants born at...
Author Contributions
Conceptualization: Park HW. Data curation: Lim G, Kim YJ, Park HW. Formal analysis: Lim G, Kim YJ, Park HW. Investigation: Lim G, Kim YJ. Methodology: Lim G, Kim YJ, Park HW. Supervision: Chung S, Park YM, Kim KS, Park HW. Writing - original draft: Lim G. Writing - review & editing: Kim YJ, Chung S, Park YM, Kim KS, Park HW.

less than 30 weeks of gestation in Korea. Apart from postnatal care, prenatal management is important to prevent BPD. Hypertension during pregnancy (HDP) has been reported as a risk factor for BPD. HDP (including pre-eclampsia) causes various prenatal morbidities, including preterm birth, intra-uterine growth restriction, and maternal complications. The placental pathology of HDP is characterized by placental insufficiency, decreased fetal perfusion, and intrauterine growth restriction; these are also risk factors for BPD. We performed this meta-analysis to examine the association between maternal HDP and neonatal BPD in the preterm infants.

METHODS
Search strategy and study selection
We searched PubMed, EMBASE, the Cochrane Library, and the KoreaMed database for relevant studies. We used the following search terms: infant, premature, neonate, pregnancy-induced hypertension, pre-eclampsia, eclampsia, hypertension, BPD, and/or chronic lung disease. The last search was performed on June 18, 2019. The titles and abstracts of all articles were initially screened, and the full-text articles were then reviewed by two authors (Park HW and Lim G) using predefined selection criteria. We excluded case reports, case series, review articles, editorials, and comments. The reference lists of included studies were manually searched, as were other electronic databases. No language restriction was imposed; studies were translated if necessary.

Inclusion and exclusion criteria
We included randomized controlled trials, observational studies (cohort studies or case-control studies), and cross-sectional studies in the analysis. Single-arm cohort studies without comparison groups, case reports, case series and animal studies were excluded. Types of HDP included gestational hypertension, pre-eclampsia-eclampsia and pre-eclampsia superimposed on chronic hypertension (based on a report from the National High Blood Pressure Education Program Working Group). The definition of elevated blood pressure (BP) varied among the studies, including systolic BP (sBP) ≥ 140 mmHg and/or diastolic BP (dBP) ≥ 90 mmHg, an increase in sBP ≥ 25 mmHg and/or dBP ≥ 15 mmHg and sBP ≥ 145 mmHg and/or dBP ≥ 95 mmHg after week 20 of gestation. Pre-eclampsia was defined as sBP ≥ 160 mmHg and/or dBP ≥ 110 mmHg with proteinuria, an increased creatinine level, a decreased platelet count, elevated hepatic enzyme levels, cerebral or visual symptoms (including headache), or persistent epigastric pain. The combination of hemolysis, elevated liver enzyme levels, and low platelet count was considered to indicate hemolysis, elevated liver enzymes, and a low platelet count (HELLP) syndrome. Eclampsia was defined as a combination of seizures and pre-eclampsia. Pre-eclampsia superimposed on chronic hypertension was defined as pre-eclampsia in women exhibiting chronic hypertension prior to pregnancy. The definition of BPD varied among studies; some used the National Institutes of Health consensus, while others defined BPD as either oxygen dependency 28 days postnatally or at 36 weeks of postmenstrual age.

Data extraction and study quality assessment
Park HW and Lim G independently extracted data via full-text review of selected studies. We recorded first author names, year of publication, country of origin, study design, period, and population; definitions of HDP and BPD, sample size, and BPD rates in the HDP and non-
HDP groups. We assessed study quality using the Newcastle-Ottawa Scale, which has three domains: selection (four items), comparability (one item), and outcomes (three items). All eight items are awarded one point, except comparability (two points). Total scores range from 0 to 9: 0–3 points reflect low quality, 4–5 points moderate quality, and ≥ 6 points high quality. Any discrepancy in quality scoring or data interpretation was resolved via discussion with a third reviewer (Park YM).

**Data synthesis and statistical analysis**

We meta-analyzed the relationship between maternal HPD and BPD using Comprehensive Meta-Analysis software (version 3.3; Biostat Inc., Englewood, NJ, USA). We used a random-effects model if heterogeneity was present and a fixed-effects model if heterogeneity was absent. We used the I² statistic to evaluate statistical heterogeneity among studies. If I² > 50%, significant between-study heterogeneity is present. We performed sensitivity analysis by removing each study individually from the analysis, and performed cumulative analyses to detect changes over time. We performed subgroup analyses according to the definition of pre-eclampsia. Funnel plot symmetry was assessed, and the Begg and Mazumdar rank correlation test and Egger regression test were performed to assess publication bias. We defined publication bias as funnel plot asymmetry or a P value < 0.05 in either the Begg and Mazumdar rank correlation test or Egger regression test. We also followed the Preferred Reporting Items for Systematic Reviews and Meta-Analysis checklist of 2009 (Supplementary Table 1).

**RESULTS**

**Literature search and selection**

A flowchart of the study inclusion/exclusion process is shown in Fig. 1. Of 1,056 studies obtained via database and manual searching, 336 duplicates were removed. Of the remaining 720 studies, 622 were excluded based on title or abstract review, and a further 63 during full text review. We finally included 35 studies.

**Characteristics of the included studies**

The characteristics of the included studies are shown in Table 1. A total of 97,399 infants were included in the meta-analysis. Based on a BPD definition of oxygen requirement at 36 weeks of gestation, the incidence of BPD was 32.0% (3,768 of 12,445 cases) in the HDP group and 29.1% (18,101 of 62,152 cases) in the non-HDP group. Based on a BPD definition of oxygen requirement at 28 days of age, the incidence of BPD was 27.6% (205 of 640 cases) in the HDP group and 25.5% (444 of 1,743 cases) in the non-HDP group. The incidence of severe BPD was 25.4% (91 of 358 cases) in the HDP group and 14.3% (144 of 1,007 cases) in the non-HDP group. The incidence of undefined BPD was 9.0% (16 of 177 cases) in the HDP group and 25.8% (64 of 248 cases) in the non-HDP group.

**Results of pooled meta-analysis**

Of the 35 eligible studies, 29 evaluated the relationship between HDP and BPD defined as an oxygen requirement at 36 weeks of gestation, and 18 evaluated the relationship when BPD was defined as an oxygen requirement at 28 days of postnatal age. Two studies evaluated the relationship between HDP and severe BPD, and three the relationship between HDP and undefined BPD. Five studies described one or more outcomes of BPD.
Regardless of the definition of hypertension, BPD was not associated with HDP in the overall analysis (odds ratio [OR], 1.131; 95% confidence interval [CI], 0.977–1.309; \( P = 0.100 \); Fig. 2). Subgroups were defined according to the definition of HDP: subgroup 1, pre-eclampsia and/or eclampsia and/or HELLP; subgroup 2, other HDP except chronic hypertension; subgroup 3, HDP including chronic hypertension. BPD was not associated with any HDP subgroup (Fig. 2).

Maternal HDP was not significantly associated with BPD defined as an oxygen dependency at 36 weeks of gestation (OR, 1.162; 95% CI, 0.991–1.362; \( P = 0.064 \); Fig. 3). In the meta-analysis of the relationship between maternal HDP and BPD based on oxygen dependency at 36 weeks of gestation, significant between-study heterogeneity was evident (\( P < 0.001; I^2 = 86.07\%) so a random-effects model was used. The Begg and Mazumdar rank correlation test (\( P = 0.302 \)), Egger regression test (\( P = 0.494 \)) and funnel plot (Supplementary Fig. 1) showed no evidence of publication bias. The data did not change when each study was sequentially removed or added (Supplementary Fig. 2).

Maternal HDP was not significantly associated with BPD defined as oxygen dependency at 28 days of age (OR, 1.084; 95% CI, 0.660–1.780; \( P = 0.751 \); Fig. 4). In the meta-analysis of the relationship between maternal HDP and BPD defined as oxygen dependency at 28 days of age, significant heterogeneity was evident among the studies (\( P < 0.001; I^2 = 78.92\%) so a random-effects model was used. Both the Begg and Mazumdar rank correlation test (\( P = 0.035 \)) and Egger regression test (\( P = 0.011 \)) revealed evidence of publication bias.
Thus, we performed trim and fill adjustments and the results did not change (OR, 1.084; 95% CI, 0.660–1.780) (Supplementary Fig. 3). No changes were seen in the sensitivity (Supplementary Fig. 4A) or cumulative (Supplementary Fig. 4B) analysis.

Maternal HDP was significantly associated with severe BPD (OR, 2.341; 95% CI, 1.726–3.174; \( P < 0.001 \); Fig. 5). There was no significant between-study heterogeneity (\( P = 0.963; I^2 = 0\%\)).
Maternal Hypertensive Disorders During Pregnancy and Severe Bronchopulmonary Dysplasia

Fig. 2. Meta-analysis of the relationship between maternal pre-eclampsia and neonatal bronchopulmonary dysplasia: subgroup analysis based on the definition of HDP. Subgroups were defined according to the definition of HDP: subgroup 1, pre-eclampsia and/or eclampsia and/or HELLP; subgroup 2, other HDP except chronic hypertension; subgroup 3, HDP including chronic hypertension. HDP = hypertension during pregnancy, HELLP = hemolysis, elevated liver enzymes, and a low platelet count, CI = confidence interval.

Fig. 3. Meta-analysis of the relationship between maternal pre-eclampsia and neonatal bronchopulmonary dysplasia defined as an oxygen requirement at 36 weeks of gestational age. HDP = hypertension during pregnancy, CI = confidence interval.
so a fixed-effects model was used. Publication bias could not be evaluated because of the small number of studies. Sensitivity and cumulative analyses revealed no significant changes.

DISCUSSION

The incidence of HDP is 2–8%.\(^9,13,14\) HDP can cause maternal and fetal complications including preterm birth, intrauterine growth restriction, and fetal death.\(^13\) Early onset (before 33 weeks of gestation) and severe disease are associated with increased risks of maternal and perinatal morbidity.\(^13,14\) HDP includes gestational hypertension, pre-eclampsia/eclampsia, pre-eclampsia superimposed on chronic hypertension, and chronic hypertension.\(^52,53\) Pre-eclampsia is defined by the American College of Obstetricians and Gynecologists as hypertension with proteinuria, or new-onset thrombocytopenia, renal insufficiency, impaired liver function, pulmonary edema, or cerebral or visual symptoms.\(^53\) Among the 35 studies included in this meta-analysis, 10 did not define HDP.\(^22,38,42-44,47,49-51,54\) HDP was diagnosed based on BP and proteinuria in 15 studies\(^8,12,16,18,21-24,26,27,31,33,34,36,37\) and on the basis of BP only in 10.\(^17,19,20,25,28-30,35,39\)

BPD is a chronic lung disease requiring oxygen or ventilator support; many antenatal and postnatal factors, and preterm birth, affect BPD development.\(^1,2\) Pre-eclampsia, one of several antenatal factors, is characterized by impaired lung alveolar and vascular development.\(^2,55\) Changes in the levels of several anti-angiogenic and angiogenic factors have been reported in women with pre-eclampsia.\(^8,15,31,56-60\) Angiogenic factors affect fetal lung development (especially pulmonary vascular growth and alveolarization) in animal models.\(^56,59,61\) It has

---

**Fig. 4.** Meta-analysis of the relationship between maternal pre-eclampsia and neonatal bronchopulmonary dysplasia defined as an oxygen requirement at 28 days of postnatal age. HDP = hypertension during pregnancy, CI = confidence interval.

**Fig. 5.** Meta-analysis of the relationship between maternal pre-eclampsia and severe bronchopulmonary dysplasia. HDP = hypertension during pregnancy, HELLP = hemolysis, elevated liver enzymes and low platelet, CI = confidence interval.
been suggested that increased levels of anti-angiogenic factors and/or inhibition of the angiogenic pathway in women with pre-eclampsia could inhibit fetal vascular or alveolar lung development; this is the “new BPD” described by Jobe and Abman. However, the strength of the relationship between HDP and BPD varied among previous reports. The BPD risk of infants born to mothers with pre-eclampsia was elevated (unadjusted OR, 1.29; adjusted OR, 1.59) in the studies of Hansen et al. and Bi et al. (unadjusted OR, 2.96; adjusted OR, 18.7). On the contrary, HDP reduced the risk of BPD in the study of Yen et al. and had no association with BPD of preterm infants in other reports. Although HDP overall was associated with BPD in the study of Bi et al., pre-eclampsia was not and pre-eclampsia/HELLP (pooled result) was only marginally associated with BPD in the unadjusted model. We found that maternal HDP was not significantly associated with BPD defined as an oxygen dependency at either 36 weeks of gestation (OR, 1.162; 95% CI, 0.991–1.362; \( P = 0.064 \); Fig. 3) or 28 days of age (OR, 1.132; 95% CI, 0.743–1.724; \( P = 0.563 \); Fig. 4), unlike previous studies. Moreover, the incidence of BPD and duration of mechanical ventilation did not differ between the pre-eclampsia and non-pre-eclampsia groups in the study of Shin et al. It is possible that we found no association between HDP and BPD (other than severe BPD) because the clinical definitions of BPD were inconsistent. The risk of BPP in the HDP group without fetal growth restriction did not differ from that of the group without HDP, and maternal HDP was associated with BPD in cases exhibiting antenatal fetal growth restriction. Dravet-Gounot et al. explored the association between fetal growth restriction and BPD in neonates born to mothers with pre-eclampsia. Pre-eclampsia onset before 34 weeks of gestation (early onset), which causes fetal growth restriction, constituted only 5–20% of all pre-eclampsia cases, most of which were late-onset and thus did not cause fetal growth restriction or changes in umbilical artery blood flow. As early onset pre-eclampsia increases the risk of neonatal morbidity, pre-eclampsia during a critical phase of development and/or the prolonged actions of anti-angiogenic and/or angiogenic factors may be associated with BPD. We assume that continued and severe pre-eclampsia causing fetal growth restriction compromises lung development and causes BPD.

We found that maternal HDP was significantly associated only with severe BPD (OR, 2.341; 95% CI, 1.726–3.174; \( P < 0.001 \); Fig. 5). Bi et al. reported an association between HDP severity and BPD but the duration of ventilator support and oxygen administration are likely to vary by clinician and medical unit; mild-to-moderate BPD does not reflect lung status. However, severe BPD always requires respiratory assistance or high concentrations of oxygen. BPD can be diagnosed without additional testing based on the physiologic definition of BPD if an infant requires over 30% oxygen or positive pressure ventilation (invasive or non-invasive). Severe BPD has been further subclassified based on the need for invasive mechanical ventilation (or not). Clinically, type 2 severe BPD is defined as a need for invasive mechanical ventilation, and is associated with poorer outcomes (including death, pulmonary hypertension, and neurodevelopmental impairment) than is type 1 BPD (defined as a need for oxygen or non-invasive mechanical support).

Our work had certain limitations. First, data on the time of HDP onset were unavailable, and we did not evaluate the associations of changes in the levels of anti-angiogenic and angiogenic factors with HDP or neonatal BPD. It was inevitable because of limitations of a meta-analysis based on only the results of previously reported studies. Second, this meta-analysis showed an association between maternal HDP and severe BPD. However, only a small number of studies have described the BPD severity. Additional clinical studies are needed to verify the relationship between maternal HDP and severe BPD.
In conclusion, we found no association between maternal HDP and neonatal BPD, other than severe BPD. Further studies should evaluate the relationships of HDP onset and/or changes in the levels of HDP-associated anti-angiogenetic and angiogenic factors with neonatal BPD.

**SUPPLEMENTARY MATERIALS**

**Supplementary Table 1**
The Preferred Reporting Items for Systematic Reviews and Meta-Analysis 2009 checklist

Click here to view

**Supplementary Fig. 1**
Funnel plot for the relationship between maternal pre-eclampsia and neonatal bronchopulmonary dysplasia defined as an oxygen requirement at 36 weeks of gestation.

Click here to view

**Supplementary Fig. 2**
Sensitivity analysis (A) and cumulative analysis (B) for the relationship between maternal pre-eclampsia and neonatal bronchopulmonary dysplasia defined as an oxygen requirement at 36 weeks of gestation.

Click here to view

**Supplementary Fig. 3**
Funnel plot the relationship between maternal pre-eclampsia and neonatal bronchopulmonary dysplasia defined as an oxygen requirement at 28 days of age. An asymmetrical funnel plot indicated possible publication bias, thus, we performed a trim and fill adjustment.

Click here to view

**Supplementary Fig. 4**
Sensitivity analysis (A) and cumulative analysis (B) for the relationship between maternal pre-eclampsia and neonatal bronchopulmonary dysplasia defined as an oxygen requirement at 28 days of age.

Click here to view

**REFERENCES**

1. Jobe AJ. The new BPD: an arrest of lung development. *Pediatr Res* 1999;46(6):641-3. [PUBMED](https://pubmed.ncbi.nlm.nih.gov/10418819/) [CROSSREF](https://doi.org/10.1203/00006490-199906000-00004)

2. Mandell EW, Abman SH. Fetal vascular origins of bronchopulmonary dysplasia. *J Pediatr* 2017;185:7-10.e1. [PUBMED](https://pubmed.ncbi.nlm.nih.gov/28053921/) [CROSSREF](https://doi.org/10.1016/j.jpeds.2016.07.021)

3. Abman SH. Bronchopulmonary dysplasia: “a vascular hypothesis”. *Am J Respir Crit Care Med* 2001;164(10 Pt 1):1755-6. [PUBMED](https://pubmed.ncbi.nlm.nih.gov/11381959/) [CROSSREF](https://doi.org/10.1164/rccm.2001.00360C)
4. Shim SY, Yun JY, Cho SI, Kim MH, Park EA. The prediction of bronchopulmonary dysplasia in very low birth weight infants through clinical indicators within 1 hour of delivery. J Korean Med Sci 2021;36(11):e81.

5. Sung TJ. Bronchopulmonary dysplasia: How can we improve its outcomes? Korean J Pediatr 2019;62(10):367-73.

6. Park HW, Lim G, Chung SH, Chung S, Kim KS, Kim SN. Early caffeine use in very low birth weight infants and neonatal outcomes: a systematic review and meta-analysis. J Korean Med Sci 2015;30(12):1828-35.

7. Jeon GW. Changes in the incidence of bronchopulmonary dysplasia among preterm infants in a single center over 10 years. Neonat Med 2020;27(1):1-7.

8. Hansen AR, Barnés CM, Folkman J, McElrath TF. Maternal preeclampsia predicts the development of bronchopulmonary dysplasia. J Pediatr 2010;156(4):532-6.

9. Bi GL, Chen FL, Huang WM. The association between hypertensive disorders in pregnancy and bronchopulmonary dysplasia: a systematic review. World J Pediatr 2013;9(4):300-6.

10. Torchin H, Ancel PY, Goffinet F, Hascoët J-M, Truffert P, Tran D, et al. Placental complications and bronchopulmonary dysplasia: EPIPAGE-2 cohort study. Pediatrics 2016;137(3):e20152163.

11. Dravet-Gounot P, Torchin H, Goffinet F, Aubelle MS, El Ayoubi M, Lefevre C, et al. Bronchopulmonary dysplasia in neonates born to mothers with preeclampsia: impact of small for gestational age. PLoS One 2018;13(9):e0204498.

12. O’Shea JE, Davis PG, Doyle LW; Victorian Infant Collaborative Study Group. Maternal preeclampsia and risk of bronchopulmonary dysplasia in preterm infants. Pediatr Res 2012;71(2):210-4.

13. Sibai B, Dekker G, Kuperminc M. Pre-eclampsia. Lancet 2005;365(9461):785-99.

14. Report of the national high blood pressure education program working group on high blood pressure in pregnancy. Am J Obstet Gynecol 2000;183(1):S1-22.

15. Mestan KK, Gotteiner N, Porta N, Grobman W, Su EJ, Ernst LM. Cord blood biomarkers of placental maternal vascular underperfusion predict bronchopulmonary dysplasia-associated pulmonary hypertension. J Pediatr 2017;185:33-41.

16. Strouss L, Goldstein ND, Locke R, Paul DA. Vascular placental pathology and the relationship between hypertensive disorders of pregnancy and neonatal outcomes in very low birth weight infants. J Perinatol 2018;38(4):324-31.

17. Spinillo A, Stronati M, Ometto A, Fazzi E, Lanzi G, Guaschino S. Infant neurodevelopmental outcome in pregnancies complicated by gestational hypertension and intra-uterine growth retardation. J Perinat Med 1993;21(3):195-203.

18. Kim CR, Vohr BR, Oh W. Effects of maternal hypertension in very-low-birth-weight infants. Arch Pediatr Adolesc Med 1996;150(7):686-91.

19. Todd DA, Jana A, John E. Chronic oxygen dependency in infants born at 24-32 weeks’ gestation: the role of antenatal and neonatal factors. J Paediatr Child Health 1997;33(5):402-7.

20. Cunha GS, Mezzacappa Filho F, Ribeiro JD. Maternal and neonatal factors affecting the incidence of bronchopulmonary dysplasia in very low birth weight newborns. J Pediatr (Rio J) 2003;79(6):550-6.

21. Akram Khan M, Kuzma-O’Reilly B, Brodsky NL, Bhandari V. Site-specific characteristics of infants developing bronchopulmonary dysplasia. J Perinatol 2006;26(7):428-35.

22. Cetinkaya M, Ozkan H, Köksal N, Karali Z, O zgür T. Neonatal outcomes of premature infants born to preeclamptic mothers. J Matern Fetal Neonatal Med 2010;23(5):425-30.
23. Schlapbach LJ, Ersch J, Adams M, Bernet V, Bucher HU, Latal B. Impact of chorioamnionitis and preeclampsia on neurodevelopmental outcome in preterm infants below 32 weeks gestational age. *Acta Paediatr* 2010;99(10):1504-9.

24. Ozkan H, Cetinkaya M, Koksal N. Increased incidence of bronchopulmonary dysplasia in preterm infants exposed to preeclampsia. *J Matern Fetal Neonatal Med* 2012;25(12):2681-5.

25. Shima Y, Kumasaka S, Migita M. Perinatal risk factors for adverse long-term pulmonary outcome in premature infants: comparison of different definitions of bronchopulmonary dysplasia/chronic lung disease. *Pediatr Int* 2013;55(5):578-81.

26. Yen TA, Yang HI, Hsieh WS, Chou HC, Chen CY, Tsou KI, et al. Preeclampsia and the risk of bronchopulmonary dysplasia in VLBW infants: a population based study. *PLoS One* 2013;8(9):e75168.

27. Morsing E, Mørk K. Pre-eclampsia - an additional risk factor for cognitive impairment at school age after intrauterine growth restriction and very preterm birth. *Early Hum Dev* 2014;90(2):99-101.

28. Gemmell L, Martin L, Murphy KE, Modi N, Håkansson S, Reichman B, et al. Hypertensive disorders of pregnancy and outcomes of preterm infants of 24 to 28 weeks’ gestation. *J Perinatol* 2016;36(12):1067-72.

29. Matic M, Inati V, Abdel-Latif ME, Kent AL; NSW ACT NICUS Network. Maternal hypertensive disorders are associated with increased use of respiratory support but not chronic lung disease or poorer neurodevelopmental outcomes in preterm neonates at <29 weeks of gestation. *J Paediatr Child Health* 2017;53(4):391-8.
40. Davey DA, MacGillivray I. The classification and definition of the hypertensive disorders of pregnancy. *Am J Obstet Gynecol* 1988;158(4):892-8. 
PUBMED | CROSSREF

41. Jobe AH, Bancalari E. Bronchopulmonary dysplasia. *Am J Respir Crit Care Med* 2001;163(7):1723-9. 
PUBMED | CROSSREF

42. Korhonen P, Tammela O, Koivisto AM, Laippala P, Ikonen S. Frequency and risk factors in bronchopulmonary dysplasia in a cohort of very low birth weight infants. *Early Hum Dev* 1999;54(3):245-58. 
PUBMED | CROSSREF

43. Hernández-Ronquillo L, Téllez-Zenteno JF, Weder-Cisneros N, Salinas-Ramírez V, Zapata-Pallagi JA, da Silva O. Risk factors for the development of bronchopulmonary dysplasia: a case-control study. *Arch Med Res* 2004;35(6):549-53. 
PUBMED | CROSSREF

44. Redline RW, Wilson-Costello D, Hack M. Placental and other perinatal risk factors for chronic lung disease in very low birth weight infants. *Pediatr Res* 2002;52(5):713-9. 
PUBMED | CROSSREF

45. Gortner L, Misselwitz B, Milligan D, Zeitlin J, Kollée L, Boerch K, et al. Rates of bronchopulmonary dysplasia in very preterm neonates in Europe: results from the MOSAIC cohort. *Neonatology* 2011;99(2):112-7. 
PUBMED | CROSSREF

46. Çetinkaya M, Çekmez F, Erener-Ercan T, Buyukkale G, Demirhan A, Aydemir G, et al. Maternal/neonatal vitamin D deficiency: a risk factor for bronchopulmonary dysplasia in preterms? *J Perinatol* 2015;35(10):813-7. 
PUBMED | CROSSREF

47. Anwar M, Ismat S, Qamber JH, Bano M. Bronchopulmonary dysplasia: a hazard factor in preterms due to maternal/neonatal vitamin D inadequacy. *Pak J Med Health Sci* 2018;12(3):1291-5.
PUBMED | CROSSREF

48. Tang JR, Karumanchi SA, Seedorf G, Markham N, Abman SH. Excess soluble vascular endothelial growth factor receptor-1 in amniotic fluid impairs lung growth in rats: linking preeclampsia with bronchopulmonary dysplasia. *Am J Physiol Lung Cell Mol Physiol* 2012;302(1):L36-46. 
PUBMED | CROSSREF

49. Tsao PN, Su YN, Li H, Huang PH, Chien CT, Lai YL, et al. Overexpression of placenta growth factor contributes to the pathogenesis of pulmonary emphysema. *Am J Respir Crit Care Med* 2004;169(4):505-11. 
PUBMED | CROSSREF

50. Bhatt AJ, Pryhuber GS, Huyck H, Watkins RH, Metlay LA, Maniscalco WM. Disrupted pulmonary vasculature and decreased vascular endothelial growth factor, Flt-1, and Tie-2 in human infants dying with bronchopulmonary dysplasia. *Am J Respir Crit Care Med* 2001;164(10 Pt 1):1971-80. 
PUBMED | CROSSREF

41/13
59. Jakkula M, Le Cras TD, Gebb S, Hirth KP, Tuder RM, Voelkel NF, et al. Inhibition of angiogenesis decreases alveolarization in the developing rat lung. *Am J Physiol Lung Cell Mol Physiol* 2000;279(3):L600-7. PubMed | Crossref

60. Leaños-Miranda A, Navarro-Romero CS, Sillas-Pardo LI, Ramírez-Valenzuela KL, Isordia-Salas I, Jiménez-Trejo LM. Soluble endoglin as a marker for preeclampsia, its severity, and the occurrence of adverse outcomes. *Hypertension* 2019;74(4):991-7. PubMed | Crossref

61. Le Cras TD, Markham NE, Tuder RM, Voelkel NF, Abman SH. Treatment of newborn rats with a VEGF receptor inhibitor causes pulmonary hypertension and abnormal lung structure. *Am J Physiol Lung Cell Mol Physiol* 2002;283(3):L555-62. PubMed | Crossref

62. Abman SH, Groothius JR. Pathophysiology and treatment of bronchopulmonary dysplasia. Current issues. *Pediatr Clin North Am* 1994;41(2):277-315. PubMed | Crossref

63. Palta M, Gabbert D, Weinstein MR, Peters ME. Multivariate assessment of traditional risk factors for chronic lung disease in very low birth weight neonates. The Newborn Lung Project. *J Pediatr* 1991;119(2):285-92. PubMed | Crossref

64. Hakulinen A, Heinonen K, Jokela V, Kiekara O. Occurrence, predictive factors and associated morbidity of bronchopulmonary dysplasia in a preterm birth cohort. *J Perinat Med* 1988;16(5-6):437-46. PubMed | Crossref

65. Shin SH, Shin SH, Kim SH, Kim YJ, Cho H, Kim EK, et al. The association of pregnancy-induced hypertension with bronchopulmonary dysplasia - a retrospective study based on the Korean Neonatal Network database. *Sci Rep* 2020;10(1):5600. PubMed | Crossref

66. Walsh MC, Yao Q, Gettner P, Hale E, Collins M, Hensman A, et al. Impact of a physiologic definition on bronchopulmonary dysplasia rates. *Pediatrics* 2004;114(5):i305-11. PubMed | Crossref

67. Abman SH, Collaco JM, Shepherd EG, Keszler M, Cuevas-Guaman M, Welty SE, et al. Interdisciplinary care of children with severe bronchopulmonary dysplasia. *J Pediatr* 2017;181:i2-28.e1. PubMed | Crossref

68. Kim HR, Jung YH, Kim BI, Kim SY, Choi CW. Differences in comorbidities and clinical burden of severe bronchopulmonary dysplasia based on disease severity. *Front Pediatr* 2021;9:664033. PubMed | Crossref